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The activation of G-Protein Coupled Receptors (GPCRs) by their respective ligands
initiates a cascade of multiple signaling processes within the cell, regulating growth,
metabolism and other essential cellular functions. Dysregulation and aberrant expression
of these GPCRs and their subsequent signaling cascades are associated with many
different types of pathologies, including cancer. The main life threatening complication
in patients diagnosed with cancer is the dissemination of cells from the primary tumor
to distant vital organs within the body, metastasis. Communication between the primary
tumor, immune system, and the site of future metastasis are some of the key events in the
early stages of metastasis. It has been postulated that the communication is mediated
by nanovesicles that, under non-pathological conditions, are released by normal cells
to relay signals to other cells in the body. These nanovesicles are called exosomes,
and are utilized by the tumor cell to influence changes within the recipient cell, such
as bone marrow progenitor cells, and cells within the site of future metastatic growth,
in order to prepare the site for colonization. Tumor cells have been shown to release
an increased number of exosomes when compared to their normal cell counterpart.
Exosome production and release are regulated by proteins involved in localization,
degradation and size of the multivesicular body, whose function may be altered within
cancer cells, resulting in the release of an increased number of these vesicles. This review
investigates the possibility of GPCR signaling cascades acting as the upstream activator
of proteins involved in exosome production and release, linking a commonly targeted
trans-membrane protein class with cellular communication utilized by tumor cells in early
stages of metastasis.
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INTRODUCTION
Increasing evidence links the aberrant protein expression of G-protein coupled receptors with
numerous pathologies, including cancer. Exosomes are membrane-bound nanovesicles that have
been implicated as an important component in preparing distal organs for tumor cell metastasis.
This review intends to explore and speculate about G-protein coupled receptors and their links to
cancer, exosomes, and the involvement in cancer metastasis.
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G-PROTEIN COUPLED RECEPTORS
Guanine nucleotide binding-protein coupled receptors (GPCRs)
make up the largest family of proteins found within the
mammalian genome (Lander et al., 2001; Venter et al., 2001).
The GPCR superfamily contains over 800 different seven trans-
membrane receptors. Two requirements must be met in order to
be classified as a GPCR; the first is that the receptor contains
seven stretches of about 30 highly hydrophobic residues that
represent trans-membrane locations, which provide the protein
with both intracellular domains and an extracellular domain
that has the ability to interact with its ligand. The second
requirement that defines a GPCR is interaction with guanine
nucleotide binding proteins (G-proteins). GPCR classification
within the superfamily is based on how the ligand binds to the
receptor, physiological, and structural features of the receptor,
as well as phylogenetics. The most frequently used classification
system is A, B, C, D, E, and F (Attwood and Findlay, 1994;
Kolakowski, 1994) which represent GPCRs from all living beings
from humans to bacteria. The majority of human GPCRs
are separated into 5 different families; glutamate, rhodopsin,
adhesion, frizzled/taste2, and secretin (GRAFS nomenclature;
Fredriksson et al., 2003; Lagerstrom and Schioth, 2008).
The natural ligands for GPCRs vary from ions, proteins, lipids,
hormones, neurotransmitters, amines, nucleotides, odorant
molecules to photons. GPCRs are associated with heterotrimeric
G-protein subunits consisting of Gα, Gβ, and Gγ, that function
as dimers at the intracellular domain of the GPCR. Once the
ligand binds to the receptor, it causes a conformational change,
activating the receptor and initiating an intracellular cascade. The
inactive form of the receptor is bound to guanine diphosphate
(GDP), and this conformational change results in the exchange
of GDP with guanine triphosphate (GTP) of the associated
G-protein within the intracellular domain of the GPCR. This
phosphate exchange alters the affinity of the G-protein with the
GPCR and results in the dissociation of that G-protein (Hamm,
1998; Bunemann et al., 2003), GPCRs can then interact with a
multitude of different targets including ion channels, tyrosine
kinases, adenylyl cyclases, phosphodiesterases, and others (Lee
et al., 2008; Lappano and Maggiolini, 2011). Disruption in the
function of GPCRs are known to be responsible for many
prevalent human diseases such as nephrogenic diabetes insipidus
(Spiegel, 1996a), cardiovascular disease (Hata and Koch, 2003),
endocrine diseases (Spiegel, 1996b; Lee et al., 2008; Lappano and
Maggiolini, 2011), and others.
The GPCRs whose natural ligands are neurotransmitters,
specifically glutamate, are classified under class C receptors
(Bjarnadottir et al., 2005), and are broken down into
metabotropic glutamate receptors (mGluR), GABA receptors,
calcium sensing receptors, taste receptors, and some orphan
receptors (Wu et al., 2014). The remainder of this review
focuses on the metabotropic glutamate receptors (mGluRs)
particularly mGluR1. The mGluRs can be broken down into
groups I through III, based on their sequence homology,
pharmacologic responses, and intracellular second messengers.
Group I consists of mGluR1 and mGluR5, group II contains
mGluR2 and mGluR3, and group III contains mGluR4, mGluR6,
mGluR7, and mGluR8 (Nakanishi, 1992). Binding of the ligand,
glutamate, to group I mGluRs resulted in exchange of GTP for
GDP on Gα. Specifically, groups II and III mGluRs are coupled
to Gαi/o. Group I mGluR activation results in the stimulation of
phospholipase C β (PLCβ) which cleaves phosphatidylinositol
4,5-bisphosphate (PIP2) into two second messengers: inositol
triphosphate (IP3), which are released into the cytoplasm,
and diacylgycerol (DAG), which remains associated with the
plasma membrane. Discharged IP3 initiates the activation of
protein kinase C (PKC), which is involved in phosphorylation of
various proteins to participate in numerous cellular functions.
The hydrolysis to the second messenger IP3 results in the
mobilization of calcium from the endoplasmic reticulum,
and the subsequent activation of various calcium dependent
kinases (Marin and Chen, 2004). The group II and III mGluRs
associated Gαi/o, once activated, prevent the formation of cAMP
by inhibiting adenylyl cyclase activity.
GPCRs AND CANCER
The first report identifying a GPCR as an oncogene was in
1986 by Wigler and co-workers when they demonstrated the
transforming activity of a rat protein, MAS (Young et al., 1986).
Unlike most oncogenes identified at that time, MAS did not have
activating mutations. Subsequent studies showed that the ability
of GPCRs to possess oncogenic potential is by either aberrant
protein expression or the excessive local production of ligands
by tumor cells themselves (autocrine) or stromal counterparts
(paracrine) and increasing the available ligand and subsequent
receptor activation (Young et al., 1986). Mutations have also been
detected inGPCRs, including a gain of functionmutation causing
amino-acid changes in G-proteins where GTP is bound. These
mutations can initiate signaling cascades independent of GPCR
activation (Van Raamsdonk et al., 2004).
Our laboratory was the first to suggest the role of dysregulated
glutamatergic signaling in melanoma pathogenesis, which was
subsequently confirmed by other investigators. It was discovered
that a gain-of-function of the murine form of a neuronal
receptor, metabotropic glutamate receptor 1 (gene: GRM1,
protein: mGluR1), when ectopically expressed in melanocytes,
was sufficient to induce in vitro melanocytic transformation
and spontaneous malignant melanoma development in vivo
in a transgenic mouse model, TG-3 (Pollock et al., 2003;
Ohtani et al., 2008; Shin et al., 2008). Subsequent investigation
revealed mGluR1 expression was also detected in 80% of
human melanoma cell lines and 65% of human melanoma
biopsy samples at levels of protein and mRNA (Pollock et al.,
2003). Earlier studies showed the aberrant protein expression
of GPCRs and the availability of abundant ligand in the
surrounding environment are involved in cell transformation
(Julius et al., 1989). We assessed levels of extra-cellular glutamate
in several melanoma cell lines. We found elevated glutamate
levels only in mGluR1-expressing melanoma cells (Namkoong
et al., 2007). We also demonstrated stimulation of mGluR1 by
its ligand, glutamate as well as other agonists, led to formation
of two second messengers, DAG and IP3, as described in the
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central nervous system (CNS; Hermans and Challiss, 2001).
DAG remains bound to the cell membrane, and activates
PKC (Newton, 2001). PKC then activates the MAPK signaling
cascade responsible for cell proliferation and inhibits apoptosis
(Marin and Chen, 2004). PKC also activates the PI3K/AKT
pathway (Spiegel, 1996a; Lappano and Maggiolini, 2011), which
is involved in tumor cell survival, epithelial-mesenchymal
transition and angiogenesis (Marin et al., 2006; Stepulak et al.,
2009). Unlike many mouse models of cancer, TG-3 displays
metastasis to several distal organs as the disease progresses (Zhu
et al., 1998). Consequently, activation of ectopically expressed
GRM1 initiates signaling cascades important for melanoma
pathogenesis, which could include activation of the exosomal
production pathway, paving the way for metastasis. In addition
to mGluR1, other mGluRs have been implicated in numerous
cancers. Table 1 summarizes various cancers associated with
mGluR misregulation.
EXOSOMES
Exosomes are small membrane-bound nanovesicles with the
characteristic size of 30–120 nm in diameter, derived from
endosomal origins, generated constitutively, and released by
various cell types andmore frequently by tumor cells (Thery et al.,
2002). Exosomes can be found in the blood (Taylor and Gercel-
Taylor, 2008), urine (Pisitkun et al., 2004), saliva (Gonzalez-
Begne et al., 2009), plasma (Caby et al., 2005), breast milk
(Admyre et al., 2007) as well as other bodily fluids (Andre et al.,
2002; Gatti et al., 2005; Keller et al., 2007; da Silveira et al.,
2012). Exosomes are actively secreted from cells by an exocytosis
pathway used for receptor removal and crosstalk between cells
(Stoorvogel et al., 2002; Thery et al., 2002; Valenti et al., 2007).
Exosomes are shed from the surface of healthy cells, and take
with them membrane proteins and cytoplasm contents of the
cells they are released from including miRNAs, mRNAs, siRNAs,
and proteins (Thery et al., 2002). Studies of exosomes from
various cell types show several common proteins contained in all
exosomes (Raposo et al., 1996; Escola et al., 1998; Thery et al.,
1999, 2001; van Niel et al., 2001).
COMPOSITION OF EXOSOMES
Exosomes contain a unique composition of proteins and nucleic
acids that can vary depending on the cell type they originated
from. Studies of exosomes from immature dendritic cells (DCs;
Thery et al., 1999, 2001), B lymphocytes (Raposo et al., 1996;
Escola et al., 1998), intestinal epithelial cells (vanNiel et al., 2001),
and other cell types show that there are common, as well as cell-
type specific proteins residing within exosomes. Cell-type specific
proteins within exosomes include Major Histocompatibility
Complex (MHC) class I and II proteins, which have been detected
in B lymphocyte, DCs, mast cells and intestinal epithelial cell
exosomes. Von Willebrand factor (Heijnen et al., 1999), perforin
and granzymes (Peters et al., 1991) were found in platelet and
cytotoxic T cell exosomes, respectively. The proteins that were
found to be consistent across exosome types include chaperones
TABLE 1 | Metabotropic glutamate receptors (mGluRs) and associated
malignancies.
Group mGluR Cancer References
I mGluR1 Malignant Melanoma Pollock et al., 2003; Marin
and Chen, 2004; Ohtani
et al., 2008
Breast Cancer Shah et al., 2012; Speyer
et al., 2012; Teh et al., 2015
Lung Kan et al., 2010
Ovary Cancer Genome Atlas
Research, 2008
Large Intestine Sjoblom et al., 2006; Wood
et al., 2007; Cancer
Genome Atlas Research,
2008
Upper Aerodigestive Tract Durinck et al., 2011;
Stransky et al., 2011
Astrocytoma Parsons et al., 2008
Glioma Brocke et al., 2010
Medulloblastoma Brocke et al., 2010
mGluR5 Malignant Melanoma Frati et al., 2000; Choi et al.,
2011
Prostate Pissimissis et al., 2009
Oral Squamous Cell
Carcinoma
Park et al., 2007
Osteosarcoma Kalariti et al., 2007
Glioma Brocke et al., 2010
Medulloblastoma Brocke et al., 2010
II mGluR2 Glioma D’Onofrio et al., 2003;
Arcella et al., 2005
Prostate Pissimissis et al., 2009
mGluR3 Glioma D’Onofrio et al., 2003;
Arcella et al., 2005
Malignant Melanoma Prickett and Samuels, 2012
III mGluR4 Colorectal Carcinoma Chang et al., 2005
Glioma Brocke et al., 2010
Malignant Melanoma Chang et al., 2005
Squamous Cell Carcinoma Chang et al., 2005
Medulloblastoma Iacovelli et al., 2006
mGluR6 Glioma Brocke et al., 2010
Medulloblastoma Brocke et al., 2010
mGluR7 N/A
mGluR8 Malignant Melanoma Choi et al., 2011; Prickett
and Samuels, 2012
Adapted from (Prickett and Samuels, 2012; Teh and Chen, 2012; Esseltine et al., 2013).
(Hsc73 and Hsc90), subunits of trimeric G proteins, Tsg101,
cytoskeletal proteins and tetraspanins such as CD9, CD63, CD81,
and CD82 (Thery et al., 1999, 2001; van Niel et al., 2001). Kahlert
et al. identified double stranded genomic DNA present within
exosomes (Kahlert et al., 2014).
FORMATION OF EXOSOMES
One of the defining characteristics of exosomes is the endocytic
origin, which sets it apart from other cellular vesicles such as
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apoptotic bodies that are budded off of the plasma membrane.
The initial step in the formation of exosomes is endocytosis.
Invagination of the plasma membrane is initiated by the
deformation of the lipid bilayer, which can be influenced
extrinsically or by internal membrane structural modification.
Specific membrane manipulating proteins interact with and
bend the membrane surface to initiate tubulation. Membranes
that are tubulated experience an external force, which causes
the inward curvature, or invagination of the membrane
(Lipowsky, 2013). The proteins involved in this process include
endocytosis proteins such as epsin (Ford et al., 2002), N-
BAR proteins, such as amphiphysin (Takei et al., 1999; Peter
et al., 2004) and endophilin, (Farsad et al., 2001) or F-
BAR proteins, such as syndapins (Wang et al., 2009) and
its associated protein, dynamin. Dynamin is a GTPase that
connects with both actin and F-BAR to successfully form
and cut membrane tubules to create a successful invagination
of the membrane. (Reviewed by Lipowsky, 2013). Once the
invaginated membrane forms and becomes severed from the
plasma membrane, it is released into the cytosol of the cell as an
endosome.
The Endosomal Sorting Complex Required for Transport
(ESCRT) functions on the newly formed endosome to initiate the
internal budding of the multivesicular bodies (MVB) membrane
to form smaller intraluminal vesicles within the MVB, these
vesicles are exosomes. Ceramide, a sphingolipid, was found to
trigger budding of exosome vesicles into the multivesicular body
(Trajkovic et al., 2008). ESCRT is made up of four different
complexes (ESCRT-0, -I, -II, and -III) and associated accessory
proteins. The primary function of the ESCRT proteins is to
constrict the membrane, create budding within the endosome
and cause severing of the budded vesicle neck to separate
the vesicle from the MVB membrane. The precise mechanism
of the severing is unknown. (Hurley and Hanson, 2010; Peel
et al., 2011; Henne et al., 2013; McCullough et al., 2013). The
proteins in the ESCRT pathway are broken up into four different
complexes: ESCRT-0, -I, -II, and -III. ESCRT-0 is involved
in collecting ubiquitinated proteins on the membrane of the
endosome. ESCRT-I and -II initiate the inward budding of
the endosomal membrane and ESCRT-III severs the budding
membrane from the endosome, creating a separate smaller vesicle
within the endosome; an exosome (Reviewed by Hurley and
Odorizzi, 2012). ESCRTIII is recruited for scission by ALIX.
Syndecans are proteins involved in sulfate-presentation on the
membrane surface, and are found on exosomes. These proteins
are sorted into exosomes by an adapter protein, syntenin, which
binds to ALIX, recruiting ESCRTIII to finalize the formation
of the exosome (Baietti et al., 2012; Hurley and Odorizzi,
2012).
The specificity of cargo sorting into these exosome vesicles
is still unclear. However, it has been shown that ubiquitination
serves as a signal for sorting cargo into the vesicles formed
within the MVB. Additionally, evidence has shown that ESCRT-I
recognizes ubiquitinated cargo, suggesting that this protein and
its associated protein, Vps23, initiate MVB sorting by binding
cargo and directing it to MVB for loading in a ubiquitin-binding
manner (Katzmann et al., 2001).
EXOSOME RELEASE
Once the MVB is formed and contains exosomes within its
membrane, it has one of two fates; targeted degradation by
the lysosome or plasma membrane fusion resulting in exosome
release.
If the MVB is targeted for lysosomal degradation, it fuses with
the lysosome and results in the release of the internal exosomes
and the macromolecules contained within them, into the lumen
of the lysosome. These components are then exposed to the
hydrolytic enzymes within the lumen of the lysosome and are
degraded (Futter et al., 1996).
Alternatively, the MVB will travel to the plasma membrane.
In this case, a GTPase, RAL-1, has recently been identified to
mediate the fusion of the MVB membrane with the plasma
membrane of the cell to allow the release of the exosomes into the
extracellular space. Syx-5 is a t-SNARE that is recruited by RAL-
1 to the plasma membrane to stimulate MVB fusion. Hyenne
et al., showed that without Syx-5, the MVB is unable to fuse with
the plasma membrane (Hyenne et al., 2015). Ostrowski et al.,
identified Rab27a, Rab27b, and their effectors (SYTL4 and Slac2b,
respectively) to be involved in the exosomal pathway in HeLa
cells (Ostrowski et al., 2010). Specifically, Rab27a was shown
to be involved in the size of the MVE, while Rab27b regulated
localization of the MVB to the plasma membrane. Another Rab-
GTPase, Rab35, was identified as a regulator in the docking or
tethering of the MVB to the plasma membrane (Hsu et al., 2010).
In addition to enzymatic involvement of exosome regulation,
intracellular levels of Ca2+ have been shown to be proportional to
exosome release (Savina et al., 2003), in addition, low pH within
the microenvironment influences the release of exosomes as well
as the uptake (Parolini et al., 2009).
In cancer, oncogenes have been shown to play a role in
exosome secretion, including a p53-regulated pathway, TSAP6,
both in-vitro (Yu et al., 2006) and in-vivo using a TSAP/Steap3-
null mouse (Lespagnol et al., 2008). As tumors become
more aggressive, the expression and activation of the enzyme
heparanase becomes upregulated. The activation of heparanase
increases the release of exosomes, as well as the cargo levels found
within the exosomes (Thompson et al., 2013).
EXOSOME UPTAKE
Once the exosomes are released from the plasma membrane,
they have the ability to travel to distant sites of the body, and/or
interact with the cells in the surrounding microenvironment.
Exosomes involved in intracellular communication contain
phosphatidylserine on their outer membrane and interacts with
T-cell immunoglobulin and mucin-domain-containing molecule
1 (Tim1), a transmembrane protein present on recipient cells
(Thery et al., 2002). This interaction initiates the engulfment
of exosomes by the recipient cell (Miyanishi et al., 2007). In
ovarian cancer cells, exosome uptake was shown by clathrin-
dependent endocytosis. Both proteins and specific glycoproteins
present on exosomes and the cell surface were shown to be
important for exosome uptake (Escrevente et al., 2011). The
transfer of major histocompatibility complex (MHC)-peptide
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complexes between dendritic cells was shown to be dependent
on the presence of intercellular adhesion molecule 1 (ICAM-1)
on exosomes. Exosomes from immature dendritic cells (DCs)
were unable to transfer MHC to other DCs, however, exosomes
from mature DCs contained ICAM-1 on the surface of the
exosomes, and resulted in transfer of MHC from the exosomes
(Segura et al., 2005). Additionally, heparin sulfate proteoglycans
(HSPGs) have been shown to act as receptors of tumor derived
exosomes (Christianson et al., 2013). Parolini et al., were the
first to show that endocytosis is not the sole route of exosome
uptake. Under certain conditions, exosomes will undergo lipid-
dependent membrane fusion with the recipient cell independent
of energy-dependent exocytosis and protein-protein interaction
(Parolini et al., 2009).
Once the exosomes enter the recipient cell, the cargo has
the potential to interact and alter the physiology of the cell.
Exosomes are also known to modulate gene expression as Valadi
and colleagues demonstrated that RNAs in mast cell exosomes
could be delivered to human andmouse mast cells leading to new
protein production in recipient cells (Valadi et al., 2007).
EXOSOMES IN CANCER
Circulating tumor cells (CTCs) are potential biomarkers for
cancer; however, depending on the stage of cancer, there can
be as few as 1-10 CTCs per mL of blood. Exosomes, however,
are found in abundance within the blood, typically, 1 × 1012
exosomes per mL of blood, making them a non-invasive and
ideal screening method for diagnostics, cancer progression and
targeted therapy (Hyun et al., 2015). Fujita et al., suggested
that exosomes have the potential to be used as biomarkers
for asthma (Fujita et al., 2014). In addition to a minimally
invasive biomarker, there have been efforts in using exosomes to
develop a new method of drug delivery to target drug-resistant
cancer. Exosome-encapsulated Paclitaxel (exoPTX) increases the
cytotoxic effects on prostate cancer cells when compared to
drug alone, and holds significant potential for the delivery of
various chemotherapeutics to treat cancers that have became
resistant to the regimen (Saari et al., 2015). In addition to drug
delivery, dendritic cell-derived exosomes are being explored for
their potential in cancer immunotherapy (Viaud et al., 2010).
Increased exosome plasma levels are observed only in patients
with advanced stage diseases (Logozzi et al., 2009; Peinado et al.,
2012). Recently, an assay was developed to detect a proteoglycan
molecule, glypican-1 (GPC1) found on extracellular vesicles in
patients with late-stage pancreatic cancer with 100% confidence.
This method is more reliable than a more common assay looking
for a tumor antigen in whole blood (Thery, 2015).
Along with the potential in using these vesicles to diagnose
and treat cancers, tumor exosomes have been shown to play
a role in the aggressiveness of cancer. These microvesicles are
more frequently released by tumor cells and may facilitate
communication within the local microenvironment and the
primary tumor (Baj-Krzyworzeka et al., 2006; Valadi et al.,
2007; Huber et al., 2008; Iero et al., 2008). Patient-derived
cancer-associated fibroblast exosomes have been shown to alter
the cellular metabolism of prostate and pancreatic tumor cells in
vitro, redirecting from oxidative phosphorylation to a glycolysis
and glutamine-dependent reductive carboxylation (Zhao et al.,
2016). This study indicates the impact exosomes released by
cells within the tumor microenvironment have on the cellular
function of the tumor cells. Communication between the tumor
microenvironment and the cancer cells supports tumor cell
dissemination and early events in metastasis (Hood et al., 2009,
2011). Exosomes may have the ability to promote metastasis via
the horizontal transfer of proteins, miRNAs and other molecules
to recipient cells (Ratajczak et al., 2006; Aliotta et al., 2010;
Balaj et al., 2011; Peinado et al., 2012). Exosomes containing
the RNA-binding protein LIN28 (which is a known marker of
poor outcome for ovarian cancer) were shown to be taken up
by recipient cells and significantly increase transcription of genes
involved in Epithelial-to-Mesenchymal Transition (EMT), cell
migration and invasion in the recipient cells (Enriquez et al.,
2015).
METASTASIS
Metastasis is the major cause of cancer-related death (Mehlen
and Puisieux, 2006) that occurs in a stepwise fashion relying
on a number of host-tumor interactions (Fidler and Hart, 1982;
Pauli et al., 1983). In order for a metastatic tumor to form, a
cell from the primary tumor must have the ability to survive
on its own, dissociate from the tumor, occupy the surrounding
tissue (Liotta and Stetler-Stevenson, 1991), enter circulation,
survive the environment of the circulatory system, invade the
distant parenchyma and proliferate on its own (Liotta and Stetler-
Stevenson, 1991). Circulating tumor cells (CTCs) can be found
in the vasculature of various organs but only in some organs
where a secondary tumor will survive and develop into sites
of metastasis (Poste and Fidler, 1980). It has been noted that
primary tumors preferentially home to particular organs. For
example, melanoma preferentially metastasizes to the lung and
brain (Fidler, 2003), therefore, successful metastatic growth is
dependent on a microenvironment that is receptive of that
particular cancer cell type (Fidler, 2003). Aberrant expression
of GPCR proteins has been suggested to play a role in the
organ-specific metastasis of cancer cells by way of enhancing
mobilization, promoting angiogenesis and proliferation (Lee
et al., 2008). To develop therapies focused on treating metastatic
diseases, understanding the molecular mechanisms of metastasis
is vital. Although the disseminated primary tumor cells are
essential to metastasis, the cells from the surrounding tumor
microenvironment are equally critical in prompting metastatic
ability.
FORMATION OF THE PRE-METASTATIC
NICHE
The formation of the pre-metastatic niche is an essential step in
successful metastatic growth. The primary tumor initiates this
formation by releasing factors into circulation and exosomes
released from the tumor have been implicated in this process.
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Peinedo et al., described the involvement of exosomes in tumor
progression and in the preparation of the pre-metastatic niche
of future secondary tumor sites in a melanoma model system
(Peinado et al., 2012). They provided evidence that exosomes
are released by the primary tumor into the circulation, which
results in the leakiness of the vasculature, as well as recruitment
of immune cells, both events are involved in pre-metastatic niche
formation (Peinado et al., 2012).
CHANGES WITHIN THE PRE-METASTATIC
ENVIRONMENT
Exosomes released by tumor cells contain factors such as
macrophage migration inhibitory factor (MIF) that influence
the physiology of the recipient cells. The engulfment of MIF-
containing exosomes promotes the release of transforming
growth factor beta (TGFβ) by Kupffer cells, which then initiates
the production of fibronectin by the hepatic stellate cells (hStCs;
Costa-Silva et al., 2015). Resident fibroblasts and cells from
the primary tumor stimulate fibronectin deposition (Kaplan
et al., 2005; Erler et al., 2009). The deposition of fibronectin
within the organs determines the location of the metastatic niche
formation (Kaplan et al., 2005). Fibronectin deposited within the
tissue causes the arrest of bone marrow derived cells (BMDC),
specifically macrophages and neutrophils, within the deposits
(Erler et al., 2009).
In addition to fibronectin, fibroblasts express Tenascin-C
(TN-C) glycoprotein, within the premetastatic site, which may
protect the cancer cells from apoptosis (O’Connell et al., 2011).
Several cytokines, as well asWnt and Ras/MAPK signaling, could
induce TN-C glycoprotein expression. TN-C is not found in
normal tissues, however, under pathological conditions, such
as inflammation and cancer, its protein expression is strikingly
increased and induces the production of angiogenic protein
factors such as MMP-9. TN-C also has been implicated to affect
steps in cancer progression including proliferation, migration,
invasion and angiogenesis. Reviewed by Tse and Kalluri (2007).
Periostin is a secretory protein also deposited within the
extracellular matrix (ECM) by fibroblasts, which acts as a bridge
that binds to TN-C as well as fibronectin and collagen (Kii et al.,
2010; Wang and Ouyang, 2012). Studies showed that periostin
did not have a direct effect on the growth of tumor cells, however,
knocking out periostin leads to a significant reduction in the
metastatic potential (Wang and Ouyang, 2012). Versican is an
extracellular matrix (ECM) proteoglycan that is expressed by
myeloid cells present in the pre-metastatic niche. It is involved
in mesenchymal to epithelial transition by decreasing phospho-
Smad2 levels, which increases proliferation and metastasis, but
does not play a role in the recruitment of immune cells or the
manipulation of the immune environment (Gao et al., 2012).
In addition to remodeling the extracellular matrix to create
greater permeability within the surrounding vasculature, which
is necessary in forming a pre-metastatic niche that is receptive
of CTCs, the vasculature is manipulated as well. Vascular
remodeling occurs to allow for the extravasation of CTCs
out of circulation, into the pre-metastatic environment. This
process is dependent on angiopoietin 2 (Angpt2), matrix
metalloproteinase 3 (MMP-3), and MMP-10. Huang et al.,
showed that knocking down these proteins reduces the vascular
permeability and decreases the infiltration of myeloid cells and
inhibits spontaneous lung metastasis in an in-vivomodel (Huang
et al., 2009).
In a breast cancer exosomemodel, themacrophages within the
lung and brain both phagocytose exosomes, which results in the
activation of NF-kB and subsequent release of pro-inflammatory
cytokines such as IL-6, TNFα, GCSF, and CCL2, which promote
metastasis development (Chow et al., 2014). Hypoxic breast
cancer cells release an amine oxidase, lysyl oxidase (LOX) that
accumulates at sites of pre-metastatic niche formation. LOX
co-localizes with metastases and crosslinks collagen within the
basement membrane and is essential for the recruitment and
adherence of myeloid cells. This crosslinking is critical for
CD11b+ myeloid cell recruitment, which led to interactions with
the collagen and production of MMP-2, breaking down collagen
into peptides that act as chemoattractants for bone marrow
derived cells (BMDCs) and circulating tumor cells (CTCs; Erler
et al., 2009).
RECRUITMENT OF IMMUNE CELLS
Exosomes have the ability to “educate” bone progenitor cells to
be receptive of and support tumor cell growth and metastasis
(Peinado et al., 2012). BMDCs express vascular endothelial
growth receptor 1 (VEGFR1), which may be responsible for
the homing of tumor cells to the pre-metastatic niche. Erler
et al., showed accumulation of VEGFR1+ BMDCs in common
sites of metastasis in the lung, within 9 days post-accumulation,
micrometastases formed and BMDCs remained within the site
(Erler et al., 2009). As described earlier, fibronectin deposition
within the pre-metastatic environment will result in the arrest of
bone marrow derived cells. When the BMDCs arrive, they form
clusters of cells in the tissue parenchyma at common sites of
metastasis before evidence of tumor cells (Kaplan et al., 2006).
VEGFR1+ hematopoietic cells (HPCs) express VLA-4, which
allows them to adhere to the newly synthesized fibronectin to
initiate the cellular clustering (Kaplan et al., 2006). Interaction
of VLA-4 with fibronectin is responsible for the ability of
HPCs to move within the bone marrow (Burger et al., 2003).
After fibronectin binding in HPCs, MMP protein expression is
enhanced with the presence of integrin signaling (Huhtala et al.,
1995; Yakubenko et al., 2000). MMP-9 functions to breakdown
basement membranes and the release of Kit-ligand and VEGF-A,
presumably to support bone marrow migrating cells that express
c-Kit (Bergers et al., 2000; Heissig et al., 2002).
Myeloid cell recruitment is influenced by the protein
expression of several inflammatory chemoattractants, which
are influenced by the primary tumor. These chemoattractants
recruit Mac1+ (macrophage antigen 1) myeloid cells to the lung.
Furthermore, Hiratsuka et al., found these chemoattractants were
involved in the ability of the tumor cells to migrate, using
pseudopodia for invasion. When the protein expression of these
inflammatory chemoattractants was abolished, migration of both
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tumor cells and Mac1+ myeloid cells was prevented (Hiratsuka
et al., 2006).
GPCRs AND EXOSOMES
A potential relationship between GPCRs and MVB formation,
exosome endocytosis, or exosome release has been suggested.
For example, the G protein-coupled pheromone receptor, Ste2,
is downregulated after activation by the transfer of the receptor
to the lumen of the vacuole by way of MVB sorting (Odorizzi
et al., 1998). However, Myers et al., showed that activation of
GPCRs result in growth factor shedding by way of proteolytic
cleavage, and not by exosome release (Myers et al., 2009).
Therefore, certain GPCRs, but not all, may play a role in the
MVB exocytosis. Some GPCRs, specifically A2A receptors, have
been shown to have the ability to be transferred by exosomes
from a source cell expressing these receptors to a target cell that
does not. Upon incubation with an A2A receptor agonist, the
target cells produced an increased amount of cAMP, suggesting
that the transferred receptor was then shown to be functionally
active within the target cell (Guescini et al., 2012). Additionally,
under cellular stress responses to neurohormonal stimulation,
cardiomyocytes are stimulated to release exosomes containing
an endogenous functional GPCR, AT1R, which, upon activation
with an AT1R agonist, results in phosphorylated-ERK (Pironti
et al., 2015). These studies suggest that functioning GPCRs can
be transferred by exosomes, influencing physiological changes
within the recipient cell. Locke et al., identified the relationship
between the activation of GPR143 by its natural ligand, L-DOPA,
in retinal pigment epithelial cells, and the release of exosomes
for intercellular communication in the eye (Locke et al., 2014).
Downstream exosome release is dependent on the interaction of
L-DOPA with the receptor, which activates Gαq, initiating the
release of calcium storage from the cell. Calciummobilization has
been suggested to play a role in the release of exosomes (Savina
et al., 2003; Pant et al., 2012).
Given the examples of GPCR activation resulting in exosome
formation, release, and uptake, it seems logical to suggest a
potential role of GPCRs in exosome biogenesis and function.
Furthermore, activated group I mGluRs promote the release
of calcium from the endoplasmic reticulum by the second
messenger, IP3, and increased intracellular calcium levels have
been suggested to result in the release of exosomes (Savina et al.,
2003; Pant et al., 2012). Interestingly, activated phospholipase C
FIGURE 1 | Proposed model of group I Metabotropic glutamate receptor (mGluR) activation and exosome release. Activation of group I mGluR by
glutamate results in the intracellular G-protein exchange of guanine diphosphate (GDP with guanine triphosphate (GTP). Exchange results in the activation of the αq/11
subunit and activation of phospholipase C (PLC). PLC then cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylgycerol (DAG) and inositol triphosphate
(IP3). IP3 initiates release of Ca
2+ from the endoplasmic reticulum. Excess intracellular Ca2+ initiates exosome formation/release through an unknown mechanism.
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(PLC) that hydrolyzes PIP2 for IP3 formation was detected within
exosomes of a leukemia cell line, suggesting that exosomes may
carry functional phospholipases to recipient cells (Subra et al.,
2010). Modulation of calcium concentration may be a potential
link between group I mGluR activation and exosome release
as depicted in Figure 1. This association between mGluRs and
exosome release may provide hints to elucidate the aggressive
nature of cancers that ectopically express mGluRs, and the role
exosomes play in the metastatic potential of the tumor, and
formation of the pre-metastatic niche.
CONCLUSIONS
Taken together, the aggressiveness and malignancy exhibited by
cancers aberrantly expressing GPCRs could be explained by the
release of a high volume of exosomes not only manipulating the
surrounding stromal of the tumor, but also preparing the sites
of future metastasis for the arrival of a circulating tumor cell.
We hypothesize that stimulation of GPCR by it ligand/agonist
initiates signaling cascades, activating a multitude of different
downstream effectors that may regulate exosomal secretion
and/or production. The precise mechanisms remain unknown.
Calcium has been proposed as one of the “factors” involved, for
example, stimulated group I mGluRs activate PLC and promote
hydrolytic cleavage of PIP2 for the formation of two second
messengers, IP3 and DAG. IP3 brings about the release of calcium
from the endoplasmic reticulum, which initiates multiple diverse
physiological alterations within the cell; one of them could be
exosome release. Therefore, it is plausible that GPCR signaling
may participate in exosome production or secretion by tumor
cells.
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